Intravenous Tranexamic Acid Reduces Perioperative Blood Loss in Reduction Mammoplasty With Immediate Implant-Based Reconstruction: A Randomized, Triple-Blinded, Placebo-Controlled Trial
Aesthetic Surgery Journal · 2026
DOI: 10.1093/asj/sjaf258 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Aesthetic Surgery Journal, 2026. Verfasst von Jerzy Kolasiński und 4 weiteren Autor:innen. Hauptthemen laut MEDLINE: Tranexamic Acid, Antifibrinolytic Agents, Blood Loss, Surgical, Mammaplasty. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Postoperative hematoma and oozing can compromise outcomes after reduction mammoplasty with immediate reconstruction. Intravenous (IV) tranexamic acid (TXA) is antifibrinolytic, but prospective evidence in this setting is limited.
Objectives
The aim of this study was to determine whether a single pre-incision dose of IV TXA reduces perioperative blood loss and fibrinolytic activation vs placebo.
Methods
In this randomized, triple-blinded, placebo-controlled trial, 60 women (American Society of Anesthesiologists I/II, 18-75 years) undergoing bilateral reduction mammoplasty with immediate implant-based reconstruction received TXA 10 mg/kg in 100 mL saline or placebo 10 min before incision. The primary outcome was total blood loss within 24 h (intraoperative suction + swab plus drain output). Secondary outcomes were perioperative changes in hemoglobin, D-dimer and fibrinogen, and complications within 30 days. Intention-to-treat analyses were performed.
Results
All patients completed follow-up. Total blood loss was lower with TXA than with placebo (mean ± standard deviation: 221.1 ± 72.4 vs 298.1 ± 90.6 mL; mean difference −77.0 mL; 95% CI, −122.4 to −31.6; P = .001). Intraoperative loss and 24 h drain output were also reduced. Postoperative D-dimer rise was attenuated with TXA (0.31 ± 0.15 vs 0.49 ± 0.22 µg/mL; P = .002); hemoglobin decline was smaller. No thromboembolic, neurologic, or allergic events occurred; no skin-flap necrosis was observed.
Conclusions
Pre-incisional IV TXA safely reduces perioperative bleeding and fibrinolytic activity after reduction mammoplasty. These findings support incorporation of IV TXA into perioperative protocols. Level of Evidence: 2 (Therapeutic) For image description, please refer to the figure legend and surrounding text.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
ORCID-Profile: Małgorzata Reysner
Zitieren
APA
Kolasiński, J., Reysner, T., Kolenda, M., Kołacz, S., & Reysner, M. (2026). Intravenous Tranexamic Acid Reduces Perioperative Blood Loss in Reduction Mammoplasty With Immediate Implant-Based Reconstruction: A Randomized, Triple-Blinded, Placebo-Controlled Trial. Aesthetic Surgery Journal. https://doi.org/10.1093/asj/sjaf258
Vancouver
Kolasiński J, Reysner T, Kolenda M, Kołacz S, Reysner M. Intravenous Tranexamic Acid Reduces Perioperative Blood Loss in Reduction Mammoplasty With Immediate Implant-Based Reconstruction: A Randomized, Triple-Blinded, Placebo-Controlled Trial. Aesthetic Surgery Journal. 2026. doi:10.1093/asj/sjaf258
BibTeX
@article{Kolasiski2026,
author = {Kolasiński, Jerzy and Reysner, Tomasz and Kolenda, Małgorzata and Kołacz, Szymon and Reysner, Małgorzata},
title = {Intravenous Tranexamic Acid Reduces Perioperative Blood Loss in Reduction Mammoplasty With Immediate Implant-Based Reconstruction: A Randomized, Triple-Blinded, Placebo-Controlled Trial},
journal = {Aesthetic Surgery Journal},
year = {2026},
doi = {10.1093/asj/sjaf258}
}
EUVIMED